Therapeutic effect of silymarin in beta-thalassemia major
Not Applicable
- Conditions
- Beta-Thalassemia major.Beta-Thalassemia major
- Registration Number
- IRCT138804022067N1
- Lead Sponsor
- Isfahan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 140
Inclusion Criteria
Inclusion Criteria: Presence of major Beta-thalassemia, age 12 years or older, iron overload condition (with serum ferritin levels between 1000-5000 ng/mL) during 6 months prior to study, regular deferoxamine administration (50 mg/kg), receiving continuous blood transfusions maintained at a hemoglobin level of 9.5 g/dl, negative CRP test at the beginning of the study Exclusion criteria: Presence of hepatitis B or C infection, positive HIV test, gastrointestinal problemss preventing absorption of an oral medication presence of chronic renal or heart failure, iron chelating therapy with iron chelators other than desferrioxamine, pregnancy
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum ferritin. Timepoint: 3 months and 6 months from beginning of the trial. Method of measurement: ELISA assay.;Liver enzymes (SGOT, SGPT, Alkaline Phosphatase). Timepoint: 3 months and 6 months from beginning of the trial. Method of measurement: ELISA assay.
- Secondary Outcome Measures
Name Time Method